We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Combination Chemo-Antibody Therapy With Fludarabine, Cyclophosphamide, and Rituximab Achieves a High Complete Remission Rate in Previously Untreated Chronic Lymphocytic Leukemia

  • Susan O’Brien, MD
Mar 1, 2001
Volume: 
15
Issue: 
3
  • Leukemia & Lymphoma

Initial treatment of chronic lymphocytic leukemia (CLL) with
fludarabine (Fludara) or fludarabine/cyclophosphamide (Cytoxan, Neosar) resulted
in complete remission (CR) rates of 28% and 35%, respectively. Recently,
rituximab (Rituxan) has been shown to have significant dose-related efficacy in
CLL and to sensitize lymphoid cells to chemotherapy. Based on these data, 68
patients with previously untreated CLL who have progressive or advanced-stage
disease (National Cancer Institute Working Group Criteria) have been entered on
a fludarabine/cyclophosphamide/rituximab protocol (fludarabine at 25 mg/m2,
cyclophosphamide at 250 mg/m2) daily for 3 days for six courses every 4 weeks.
Rituximab is given at 375 mg/m2 on day 1 of course 1 and 500 mg/m2 on day 1 of
courses 2 through 6.

Thirty-five patients are evaluable after six courses and 21
patients are evaluable after three courses. The patients were younger than usual
(median age: 58 years; range: 36 to 83 years) and 40% were Rai stage III/IV with
a median white blood cell count of 111 × 103/mL. The results by course number
are as follows:

 Toxicities associated with the first infusion of rituximab were
mainly fever and chills or changes in blood pressure. Toxicity grade was I/II in
61% and grade III/IV in 14%. Reactions to rituximab in courses 2 through 6 were
uncommon. Toxicities associated with fludarabine/cyclophosphamide were nausea in
21% of courses associated with vomiting in 7%. Alopecia was noted in one
patient. Major (pneumonia 1.1%, septicemia 1.9%) and minor infections (fever of
unknown cause 4.2%, herpes infection 1.5%, soft tissue infection 4.2%) occurred
in 13% of courses. Opportunistic infections were not noted. Neutropenia was the
most common hematologic toxicity leading to dose reduction of
fludarabine/cyclophosphamide in 21% of patients. No hemolytic anemia has been
noted. Chemical (3 patients) and clinical (2 patients) tumor lysis was noted
before allopurinol prophylaxis was initiated. One patient died of pneumonia
after the second course.

As shown above, a high response rate is noted after three
courses. After six courses, all responders except two PRs had < 5% CD5- and
CD19-coexpressing lymphocytes (median: 0.8%) in the marrow. Four of 10 CR
patients studied became polymerase chain reaction (PCR)-negative for
immunoglobulin heavy-chain rearrangement.

CONCLUSION: Fludarabine/cyclophosphamide/rituximab is the most
active regimen explored by our group in previously untreated CLL. The toxicity
profile is similar to that seen with fludarabine/cyclophosphamide alone.

Click here to read Dr. Bruce Cheson's commentary on this abstract.

Related Articles

  • BCR-ABL1 Levels Can Predict Sustained Deep Molecular Response in CML
  • Rituximab Does Not Improve Outcomes in Primary CNS Lymphoma
  • Adding Brentuximab to BEACOPP Promising in Relapsed Hodgkin Lymphoma
  • Integrating Genetics, MRD Improves Risk Stratification in Childhood ALL
  • Breast Implants Linked to Anaplastic Large-Cell Lymphoma

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.